Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 15/20 | 0.44 |
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025164 | 0.84 | BAZ2B (0.47) | HCAR3NNMTNPC1HTTRAB9A | |
| SCHEMBL13499099 | 0.83 | RAB9A (0.57) | HCAR3NNMTNPC1HTTRAB9A | |
| SCHEMBL14262189 | 0.80 | HCAR3 (0.46) | HCAR3NNMTRAB9ASMN1; SMN2HCAR2 | |
| SCHEMBL10014112 | 0.80 | HCAR3 (0.46) | HCAR3NNMTRAB9AHCAR2KCNJ1 | |
| SCHEMBL22644579 | 0.80 | RAB9A (0.54) | NNMTNPC1HTTRAB9ACDK5 | |
| SCHEMBL18786347 | 0.78 | SMN1; SMN2 (0.55) | HCAR3NNMTNPC1HTTRAB9A | |
| SCHEMBL12588541 | 0.75 | HCAR3 (0.72) | HCAR3NNMTHCAR2KCNJ1 | |
| SCHEMBL11005841 | 0.74 | NNMT (0.53) | HCAR3NNMTHCAR2KCNJ1 | |
| SCHEMBL1695281 | 0.74 | RAB9A (0.47) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7093993 | 0.74 | PTK2 (0.62) | HCAR3NNMTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212095-A1 | MOLECULES THAT ENHANCE EXTRACELLULAR VESICLE RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20220152188-A1 | TLR4-TLR7 LIGAND FORMULATIONS AS VACCINE ADJUVANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-19 | — | — | US | disclosed |
| US-20210380546-A1 | VACCINE ADJUVANT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-09 | — | — | US | disclosed |
| US-20210038742-A1 | CONJUGATION OF TLR7 AGONIST TO NANO-MATERIALS ENHANCES THE AGONISTIC ACTIVITY | HUANG CHING HSIN (US) | 2021-02-11 | — | — | US | disclosed |
| US-20180110784-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | disclosed |
| US-20180110784-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | disclosed |
| EP-2903987-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2017-09-20 | — | — | EP | disclosed |
| US-9540407-B2 | Phospholipid drug analogs | UROGEN PHARMA LTD (IL) | 2017-01-10 | — | — | US | disclosed |
| US-9540407-B2 | Phospholipid drug analogs | UROGEN PHARMA LTD (IL) | 2017-01-10 | — | — | US | disclosed |
| WO-2016164640-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | CARSON DENNIS A (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
| WO-2011139348-A9 | USES OF PHOSPHOLIPID CONJUGATES OF SYNTHETIC TLR7 AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011139348-A2 | USES OF PHOSPHOLIPID CONJUGATES OF SYNTHETIC TLR7 AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011134669-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134668-A1 | PHOSPHOLIPID DRUG ANALOGS | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| US-20100210598-A1 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210598-A1 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2010093436-A2 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | CARSON DENNIS A (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2008115319-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | CD4, IL4, CCR4 | HCAR3 400/4885NNMT 2248/4885NPC1 4818/4885 |
| US-20220152188-A1 | TLR4-TLR7 LIGAND FORMULATIONS AS VACCINE ADJUVANTS | TLR7, TLR4, TLR3 | HCAR3 389/4885NNMT 3707/4885NPC1 1057/4885 |
| US-20210038742-A1 | CONJUGATION OF TLR7 AGONIST TO NANO-MATERIALS ENHANCES THE AGONISTIC ACTIVITY | TLR7, TLR9, TLR3 | HCAR3 420/4885NNMT 3647/4885NPC1 593/4885 |
| US-20210380546-A1 | VACCINE ADJUVANT | IFNG, TLR9, LY96 | HCAR3 2673/4885NNMT 2631/4885NPC1 2272/4885 |
| US-20100210598-A1 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | TLR3, TLR1, TLR6 | HCAR3 138/4885NNMT 478/4885NPC1 689/4885 |
| US-20180110784-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | TLR4, TLR9, TLR1 | HCAR3 129/4885NNMT 917/4885NPC1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.